Literature DB >> 23207622

Delta-like ligand 4 correlates with endothelial proliferation and vessel maturation in human malignant glioma.

Zhi-Qiang Li1, Ling-Ling Gong, Zhi-Hua Wen, Jiang Wang, Cheng-Shi Xu, Xiao-Dong Huang.   

Abstract

AIM: To investigate the role of delta-like ligand 4 (DLL4) in the angiogenesis of high-grade malignant glioma.
MATERIALS AND METHODS: DLL4 expression and microvessel density (MVD) were detected by immunohistochemistry in 51 human high-grade malignant glioma tissue samples. The vessel maturation index (VMI) was calculated as the percentage of a-smooth muscle actin (a-SMA)-positive vessels in relation to the amount of CD31-positive vessels. Double fluorescent immunostaining for CD31 and EphrinB2 or EphB4 was performed to identify the arterial (EphrinB2) or venous (EphB4) origins of glioma microvessels.
RESULTS: Strong immunostaining of DLL4 and a positive correlation of DLL4 with the MVD were observed in high-grade malignant gliomas. The VMI of the DLL4-positive group was significantly higher than that of the DLL4-negative group. However, no significant association was found between DLL4 and EphrinB2 or EphB4 in high-grade gliomas.
CONCLUSION: DLL4 may be an important regulator for vessel proliferation and maturation in human high-grade malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23207622     DOI: 10.1159/000345116

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  8 in total

1.  The vascular delta-like ligand-4 (DLL4)-Notch4 signaling correlates with angiogenesis in primary glioblastoma: an immunohistochemical study.

Authors:  Jin-Feng Zhang; Yao Chen; Xian-Xin Qiu; Wen-Long Tang; Jian-Dong Zhang; Jian-Huang Huang; Guo-Shi Lin; Xing-Fu Wang; Zhi-Xiong Lin
Journal:  Tumour Biol       Date:  2015-10-15

2.  Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk.

Authors:  Eggehard Holler; Tao Sun; Rameshwar Patil; Anna Galstyan; Dmytro Klymyshyn; Hui Ding; Alexandra Chesnokova; Webster K Cavenee; Frank B Furnari; Vladimir A Ljubimov; Ekaterina S Shatalova; Shawn Wagner; Debiao Li; Adam N Mamelak; Serguei I Bannykh; Chirag G Patil; Jeremy D Rudnick; Jethro Hu; Zachary B Grodzinski; Arthur Rekechenetskiy; Vida Falahatian; Alexander V Lyubimov; Yongmei L Chen; Lai S Leoh; Tracy R Daniels-Wells; Manuel L Penichet; Alexander V Ljubimov; Keith L Black; Julia Y Ljubimova
Journal:  Cancer Res       Date:  2019-01-18       Impact factor: 12.701

3.  PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B.

Authors:  Bin Zhou; Hui Wang; Ren Liu; Mengzhe Wang; Huaifu Deng; Benjamin C Giglio; Parkash S Gill; Hong Shan; Zibo Li
Journal:  Mol Pharm       Date:  2015-08-28       Impact factor: 4.939

4.  Delta-like ligand 4 (DLL4) in the plasma and neoplastic tissues from breast cancer patients: correlation with metastasis.

Authors:  Emmanuel Kontomanolis; Marianthi Panteliadou; Alexandra Giatromanolaki; Stamatia Pouliliou; Eleni Efremidou; Vassilios Limberis; Georgios Galazios; Efthimios Sivridis; Michael I Koukourakis
Journal:  Med Oncol       Date:  2014-04-03       Impact factor: 3.064

Review 5.  Eph receptors as therapeutic targets in glioblastoma.

Authors:  B W Day; B W Stringer; A W Boyd
Journal:  Br J Cancer       Date:  2014-08-21       Impact factor: 7.640

Review 6.  The Role of DLLs in Cancer: A Novel Therapeutic Target.

Authors:  Meng-Xi Xiu; Yuan-Meng Liu; Bo-Hai Kuang
Journal:  Onco Targets Ther       Date:  2020-05-07       Impact factor: 4.147

Review 7.  EphrinB2-EphB4 Signaling in Neurooncological Disease.

Authors:  Andras Piffko; Christian Uhl; Peter Vajkoczy; Marcus Czabanka; Thomas Broggini
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

Review 8.  Tumor Microenvironment in Glioma Invasion.

Authors:  Sho Tamai; Toshiya Ichinose; Taishi Tsutsui; Shingo Tanaka; Farida Garaeva; Hemragul Sabit; Mitsutoshi Nakada
Journal:  Brain Sci       Date:  2022-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.